As per the Notice, starting from Jan. 1, 2023, China mandates that all documents for drug registration applications, as well as supplemental documents sent during the review, shall be submitted in electronic format on compact disks, eliminating the need for paper-based submissions. 

The Notice also outlines the specified structure of application dossiers and technical requirements for the compact disks. 

Related article: https://baipharm.chemlinked.com/news/china-requires-electronic-submission-of-all-drug-registration-application-documents-from-jan-1-2023